tbuckley/cabot-search huggingface dataset:
CMV Immunity Status in Older (&amp;gt;50 Years Old) Subjects after Non-Myeloablative or Reduced Intensity Regimen for Hematopoietic Cell Transplantation (HCT): A Comparison with a Younger Cohort after Ablative HCT.
Authors: Ghislaine Gallez-Hawkins, Lia Thao, Simon F. Lacey2, Joybelle Martinez, Anne E. Franck, Xiuli Li, Norma A. Lomeli, Ricardo Spielberger, Ryotaro Nakamura, Stephen J. Forman, Don J. Diamond, John A. Zaia
Journal: Blood (2005)
Abstract 3799: Cordyceptin induces apoptosis through repressing hTERT expression and inducing extranuclear export of hTERT
Authors: Nam Deuk Kim, Gi-Young Kim, Yung Hyun Choi
Journal: Cancer Research (2015)

Abstract Cordycepin is an adenosine analog originally extracted from Cordyceps militaris that possesses many pharmacological effects including immune activation and antioxidant and antitumor effects. However, the underlying relationship between apoptosis and telomerase activity in response to cordycepin exposure has not been investigated. In this study, we found that cordycepin-induced apoptosis of human leukemia cells (H937 and THP-1 cells) was associated with inactivation of telomerase and downregulation of human telomerase reverse transcriptase (hTERT) as well as the transcription factors c-Myc and Sp1, which are required for basal transcription from the hTERT gene promoter. Cordycepin also attenuated the activation of phosphoinositide-3-kinase (PI3K)/Akt signaling, thereby reducing phosphorylation and nuclear translocation of hTERT. We further showed that the PI3K inhibitor LY29004 significantly decreased telomerase activity in cordycepin-treated cells and increased cordycepin-induced cell death. These findings demonstrate that cordycepin is cytotoxic to human leukemia cells and suppresses telomerase activity through transcriptional and post-translational suppression of hTERT by inactivating the PI3K/Akt signaling pathway. Citation Format: Nam Deuk Kim, Gi-Young Kim, Yung Hyun Choi. Cordyceptin induces apoptosis through repressing hTERT expression and inducing extranuclear export of hTERT. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3799. doi:10.1158/1538-7445.AM2015-3799
CBM-09CD15 AND CD15S EXPRESSION IS CORRELATED WITH CELL CYCLE ARREST AT G1-PHASE IN GLIOMA
Authors: Samah Jassam
Journal: Neuro-Oncology (2015)

BACKGROUND: CD15 and sialyl-CD15 are cell surface epitopes, known for their ability to bind specific ligands. They are over-expressed on many non-central nervous system (CNS) cancers. Few reports show CD15 expression in CNS neoplasms and in fact, early studies reported the absence of CD15 expression. Recent published reports, however, have identified CD15 as a potential marker for cancer stem-like cells in glioblastomas (GBM). To obtain a better understanding, CD15 and CD15s expression was re-examined in glioma cell lines. METHOD: Extracellular expression of CD15 and CD15s were determined by Immunocytochemistry Western blot and flow cytometry in GBM cells (UP-007 and SNB-19). Non-neoplastic astrocytes (SC-1800) served as controls. Cells were synchronised at G1, S or G2/M phases via serum starvation, Hydroxyurea and Colcemid, respectively followed by validation using the fluorescence ubiqutination cell cycle indicator (FUCCI) system. RESULTS: In non-synchronised GBM cell cultures, approximately 5% of cells express CD15 or CD15s compared to 1% of CD15 or CD15s positivity in SC-1800. When GBM cell lines were synchronised in specific phases, there was a significant increase in CD15 (20%) and CD15s (46.3%) expression, especially G1 phase. The population of CD15 positive cells was significantly increased (p < 0.001) in UP-007 (CD15: 15% and CD15s:36%) and SNB-19 (CD15:20% and CD15s:15%) compared to non-synchronised GBM cells and synchronised SC-1800 (CD15:1.5% and CD15s:1.8). CONCLUSION: CD15 and CD15s expression is cell cycle dependent in glioma cells and may account for the discrepancy of previous experimental data.
Abstract LB-296: Small RNA profiling of human testicular germ cell tumor tissue samples shows abundant tRNA fragments and global loss of piRNA
Authors: Trine B. Rounge, Kari Furu, Rolf Skotheim, Trine B. Haugen, Espen Enerly, Tom Grotmol
Journal: Cancer Research (2015)

Abstract Small non-coding RNAs play essential roles in tumorigenesis. However, their role in testicular germ cell tumor (TGCT), the most common malignancy in young males in most western countries, is largely unknown. In particular, a comprehensive analysis of the small RNA composition, including microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), and tRNA-derived small RNAs and their interactions, are lacking. tRNA-derived small RNAs have been shown to bind to the piRNA-associated protein HIWI2, indicating crosstalk between small RNA pathways. We have employed small RNA sequencing on 22 human TGCT samples from 5 histological subtypes, 3 carcinoma in situ, and 12 normal testis samples. The sequences from each sample group were analyzed according to sequence length, base composition, and their association with repeats, exons, tRNAs, piRNAs, and miRNAs. Most sequences 24-32 nucleotides in length, displayed piRNA characteristics. Expression analyses of the small RNA contigs demonstrated global loss of small RNAs in TGCT compared to normal testis. A large proportion of the 33-36 nt RNA sequences derives from mature tRNAs, predominantly from the 5′ end. We did not identify differences in the expression of 5′ tRNA halves between normal and cancer tissue samples; however, 3 shorter 5′ tRNA fragments showed differential expression. Although components of the same pathways might be involved in piRNA and tRNA-derived small RNAs biogenesis, expression differences in TGCT samples suggest independent regulation of key components in response to the carcinogenic process. Our results show subtype-specific microRNA expression, as well as a global loss of piRNAs in all TGCT histological subtypes when compared to normal testicular tissue. In addition, we document the presence of large amounts of tRNA-derived sequences in both TGCT and normal samples, which may provide new insight into the association between the tRNA fragments and piRNA biogenesis. These results may be valuable in the identification of new biomarkers for TGCT. Citation Format: Trine B. Rounge, Kari Furu, Rolf Skotheim, Trine B. Haugen, Espen Enerly, Tom Grotmol. Small RNA profiling of human testicular germ cell tumor tissue samples shows abundant tRNA fragments and global loss of piRNA. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-296. doi:10.1158/1538-7445.AM2015-LB-296
Real-World Study of Dabigatran Etexilate for Thromboprophylaxis in Over 5000 Hip or Knee Replacement Patients: Favourable Safety Profile in Subgroups with Different BMI, Renal Function and Age
Authors: Nadia Rosencher, Simon Frostick, Martin Feuring, Eva Kleine, Martina Brueckmann, Andreas Clemens, Charles Marc Samama
Journal: Blood (2012)
Neoadjuvant Chemotherapy (NC) with or without Anthracyclines in different Invasive Breast Cancer (IBC) subtypes: outcomes according to pathological complete response (pCR) and proliferation index (PI) of residual tumor (RT)
Authors: A. Ferro, A. Caldara, R. Triolo, O. Caffo, C. Trentin, M. Barbareschi, F. Maines, S. Brugnara, M. Frisinghelli, V. Murgia, M. Dipasquale, F. Valduga, A. Veccia, D. Mangiola, S. Macrini, E. Galligioni
Journal: Annals of Oncology (2015)
Survival Analysis in Patients with Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation, a Single Center Study (1994-2013)
Authors: Susanne Hofmann, Lisa Müller, Stephanie Harsdorf, Christian Langer, Peter Liebisch, Jochen Greiner, Hartmut Döhner, Donald Bunjes
Journal: Blood (2014)
508. Alpha-1 Antitrypsin (AAT) Gene and Stem Cell Based Therapies for the Treatment of Osteoporosis
Authors: Mohammad A. Akbar, Yuanqing Lu, Mong-Jen Chen, Ahmed S. Elshikha, Rubina Ahamed, Mark L. Brantly, Lung-ji Chang, Lexie S. Holliday, Jay J. Cao, Sihong Song
Journal: Molecular Therapy (2015)

Osteoporosis, a serious public health problem affecting millions of Americans, is characterized by reduced bone mass and poor bone microarchitecture which can result in fractures. Although the etiology and pathogenesis of osteoporosis are complex and multifactorial, inflammation is clearly involved in the disease development. Therefore, anti-inflammatory strategy holds great potential for the prevention and treatment of this disease. Alpha 1 antitrypsin (AAT) is a multifunctional protein with anti-inflammatory, proteinase inhibitory and cytoprotective properties. We previously showed that AAT therapy had therapeutic effect in inflammation related disease models including type 1 diabetes, rheumatoid arthritis and stroke. In this study, we tested the effect of AAT on osteoclastogenesis and the therapeutic potential of AAT for preventing bone loss in an ovariectomized (OVX) mouse model. In vitro studies showed that AAT significantly inhibited osteoclast formation in a dose-dependent manner. AAT also inhibited the gene expressions of TNF-alpha and receptor activator of nuclear factor kappa B (RANK) in the early and late stages of osteoclast differentiation. To test the protective effect of AAT on osteoporosis, OVX mice were injected with either clinical grade AAT (2 mg/mouse/3 days), recombinant adeno associated virus vector expressing AAT (rAAV8-CB-AAT, 1×1011 particles/mouse), mesenchymal stem cells (MSCs) infected with lentiviral vector expressing AAT (MSC-Lenti-AAT) or PBS (100 microliter/mouse/3 days). We used age-matched and sham operated animals as a normal control. Eight weeks after the treatment, all animals were sacrificed and subjected to μCT scanning for the evaluation of vertebra bone microarchitecture including trabecular BV (bone volume), TV (Total volume), BV/TV (bone volume density), Tb.N (trabecular number), Tb.Th (trabecular thickness), Conn.Dn (connectivity density), Tb.Sp (trabecular separation) and SMI (structure model index). Results from this study showed that AAT therapies (protein, gene and stem cell-based) significantly increased TV/BV and Tb.N, and decreased SMI compared to PBS injection in OVX mice. Gene therapy also increased Conn.Dn and Tb.Th compared to PBS injection in OVX mice. These results demonstrate that AAT protein, gene and MSCs based therapies mitigate ovariectomy-induced bone loss in mouse model. Since AAT protein and gene therapies have been proven to be safe in humans, our results not only demonstrate novel functions of AAT, but also imply a new strategy for the treatment of osteoporosis.
Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome
Authors: Meritxell Nomdedeu, Xavier Calvo, Arturo Pereira, Dolors Costa, Carmen Pedro, Maria Teresa Cedena, María López-Pavía, Ana Africa Martín, Montserrat Martínez de Sola, Brayan Marcel Merchan, Maria Teresa Ardanaz, Jordi Esteve, Francesc Cobo, Guillermo F. Sanz, Benet Nomdedeu
Journal: Blood (2014)
Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line.
Authors: Betty J. Glinsmann-Gibson, Kelly A. Cycon, Shawn P. Murphy, Thomas P. Miller, Thomas M. Grogan, Margaret E. Tome, Margaret M. Briehl, Lisa M. Rimsza
Journal: Blood (2006)
Role of external beam radiation therapy (XRT) for palliation in recurrent ovarian cancer.
Authors: S. Bush, N. Jegadeesh, J. Bandyopadhyay, M. S. Macfee, S. A. Ghamande
Journal: Journal of Clinical Oncology (2011)

e19669 Background: To investigate the role of XRT in the treatment and palliation of recurrent ovarian cancer. Methods: A total of 28 patients (pts) with recurrent ovarian, primary peritoneal, or fallopian tube cancer who received XRT were identified in this retrospective single institution study. Patients receiving whole abdomen radiation were excluded. We recorded the stage, grade, progression free survival (PFS), overall survival (OS), dose of radiation, complications, response, and site of radiation. Results: The study population had a median OS of 11.8 mo (95% CI 8.2-15.3), and a PFS of 7.4 mo (95% CI 1.7-13.1). Most patients received Pelvic XRT with a median dose of 45 Gy (range 15-70.2) and 79% of these patients were platinum resistant. The median number of prior lines of chemotherapy was 3 (range 1-6). Radiation was relatively well tolerated with few complications: 7 pts had grade 2 radiation enteritis, 2 cases of grade 2 radiation cystitis, 1 case of sacral insufficiency fractures, and 1 case of lymphedema. 74% were treated with a full prescribed dose of XRT that was at least 40 Gy. The PFS was significantly longer in those treated with greater than 40 Gy 11.6 mo (95% CI 7.5-15.6) compared to 1.2 mo (95% CI 0.4-1.9) with a p value of 0.018.The OS for pts given greater than 40 Gy was significantly more than those given less than 40 Gy 18.8 mo (95% CI 0.8-36.7) and 1.2 mo (95% CI 0.4-1.9) respectively with a p value of 0.043. For comparison, 10 phase 2 co-operative group trials for recurrent platinum resistant disease, with reported response rates and survival data were identified on pub med. Analysis of these 10 studies showed an overall response rate of 13%, the median PFS was 3.3 months and median OS was 10 months. Conclusions: Our study shows that using XRT in select patients with recurrent ovarian cancer can be an effective modality for palliation yielding lasting results that are comparable if not superior to prospective phase II chemotherapy trials.
Importance of the Polymorphisms of the Thiopurine S-Methyltransferase Gene (TMPT) Determination in Mexican Mestizo Patients with Acute Lymphoblastic Leukemia (ALL).
Authors: Myrna Candelaria, Lucia Taja-Chayeb, Silvia Vidal, Olga Gutierrez, Alfonso Dueñas-Gonzalez
Journal: Blood (2007)
Encapsulation of Insulin-Secreting Cells Expressing a Genetically Encoded Fluorescent Calcium Indicator for Cell-Based Sensing In Vivo
Authors: Christophe Boss, Umberto De Marchi, Aurélie Hermant, Mouna Conrad, Federico Sizzano, Alessio Palini, Andreas Wiederkehr, Nicolas Bouche
Journal: Advanced Healthcare Materials (2016)

The development of cell-based biosensors that give insight into cell and tissue function in vivo is an attractive technology for biomedical research. Here, the development of a cell line expressing a fluorescent calcium sensor for the study of beta-cell function in vivo is reported. The bioresponsive cell model is based on INS-1E pancreatic beta-cells, stably expressing the genetically encoded cameleon-based fluorescent sensor YC3.6cyto . Following single-cell selection and expansion, functional testing and in vitro encapsulation experiments are used to identify a suitable clone of INS-1E cells expressing the calcium sensor. This clone is transplanted subcutaneous in mouse using a cell macroencapsulation system based on flat sheet porous membranes. Cells in the implanted capsules are able to respond to glucose in vivo by secreting insulin and thereby contributing to the regulation of glycaemia in the mice. Furthermore, fluorescence imaging of explanted devices shows that encapsulated cells maintain high level expression of YC3.6cyto in vivo. In conclusion, these data show that encapsulated INS-1E cells stably expressing a genetically encoded calcium sensor can be successfully implanted in vivo, and therefore serve as biosensing element or in vivo model to longitudinally monitor the function of pancreatic beta-cells.
Abstract 2618: Gemcitabine based peptide conjugates: Overcoming the pitfalls of conventional therapies by targeted approaches
Authors: Constantin Tamvakopoulos, Theodoros Karampelas, Orestis Argyros
Journal: Cancer Research (2015)

Abstract Although gemcitabine has been proved to be a valuable ally against several types of cancer, it is characterized by some weaknesses that limit its anticancer potential. These limitations are mainly associated with gemcitabine rapid inactivation as well as the different types of resistance that are related with its use. We have previously shown that conjugation of gemcitabine to a ligand peptide (molecule GSG) enhanced its metabolic stability systemically and locally (within the cancer cell), and lead to improved efficacy in a castration resistant prostate cancer (CRPC) animal model. In order to refine our previous findings, a bioanalytical methodology based on mass spectrometry that allows the simultaneous monitoring of gemcitabine as well as its active (dFdCDP, dFdCTP) and inactive (dFdU) metabolites was developed in the context of this study. The balance of gemcitabine and its active/inactive metabolites was evaluated in in vitro and in vivo systems after treatment with gemcitabine or selected gemcitabine based peptide conjugates (GSG). Furthermore, since GSG's structure contains a potent agonist peptide of the GnRH-R we investigated whether it could have a central effect through the pituitary by performing testosterone measurements in animals dosed with GSG. Interestingly, GSG appears to offer metabolic advantages in comparison to gemcitabine, an important attribute if we had to overcome gemcitabine acquired resistance. In addition, GSG is a potent GnRH-R agonist based on our in vivo biomarker model, suggesting that testosterone ablation might also represent a key attribute of the mechanism of action for our conjugate of interest. These findings along with the targeted delivery nature of this approach could ameliorate the therapeutic status of gemcitabine and expand the use of gemcitabine based conjugates in other types of cancers. Citation Format: Constantin Tamvakopoulos, Theodoros Karampelas, Orestis Argyros. Gemcitabine based peptide conjugates: Overcoming the pitfalls of conventional therapies by targeted approaches. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2618. doi:10.1158/1538-7445.AM2015-2618
PWE-036 Allergy in orofacial granulomatosis and inflammatory bowel disease
Authors: P Patel, H Campbell, J Brostoff, M Escudier, M Lomer, S J Challacombe, J D Sanderson
Journal: Gut (2010)

<h3>Introduction</h3> Orofacial granulomatosis (OFG), including oral Crohn9s disease (CD) is a chronic inflammatory condition presenting characteristically with lip swelling but also affecting a number of other sites in the oral cavity. Bouts of acute swelling and frequently reported atopy suggest an allergic component. There is evidence for dietary triggers with objective improvement on a cinnamon and benzoate-free diet.1 The Oral Allergy Syndrome (OAS) is a well recognised condition with a clear immunological pathogenesis.2 There are similarities between OAS and OFG in terms of symptoms, triggers and treatment regimes. The role of allergy in inflammatory bowel disease (IBD) remains unclear with conflicting data in the literature. <h3>Methods</h3> We performed skin prick tests to common allergens in a cohort of 88 patients with biopsy proven OFG between August 2007 and July 2009. We measured Specific serum IgE levels to relevant allergens and total serum IgE levels. The prevalence of OAS in patients with OFG was also determined. For comparison, a group of 121 consecutive patients with a confirmed diagnosis of IBD without oral involvement were also studied. <h3>Results</h3> The incidence of clinical allergy of 82% in the OFG cohort was considerably higher than the 4–20% incidence reported in the general population. OAS incidence was 28%, also significantly higher than population estimates. OFG patients with disease onset below 30 years and no concomitant CD had a significantly higher incidence of allergy (95%) and OAS (38%). ImmunCAP and total serum IgE levels also confirmed increased allergy. Allergy in CD (39%) was higher than the general population, especially in the colonic (43%) and ileocolonic (52%) compared to the ileal group (24%). Allergy in Ulcerative colitis was comparable to population estimates (18%). <h3>Conclusion</h3> Patients with OFG have an astonishingly high incidence of allergy. A large proportion of patients have OAS. A novel subepithelial dendritic B cell population demonstrating class switching to IgE, described in oral biopsies from patients with OFG by our group, could provide the link between dietary antigens, chronic oral inflammation and symptoms of hypersensitivity.3 The comparative significance of the differences in allergy in the different IBD groups remains unclear.
Abstract 1303: Quantification of natural killer cell-mediated cytotoxicity using Celigo imaging cytometry
Authors: Leo Li-Ying Chan, Kelsey Rosbach, Srinivas S. Somanchi, Dean Lee
Journal: Cancer Research (2015)

Abstract Cytotoxicity assays play a central role in studying the function of immune effector cells such as cytolytic T lymphocytes (CTL) and natural killer (NK) cells. Traditionally, cytotoxicity assays have been performed using 51Chromium (51Cr) and Calcein release assays. The assays involve labeling tumor cells (target) with radioisotope or fluorescent dyes, when the target cells are subjected to cytolysis by CTLs or NK cells (effector), they releases the entrapped labels into the media upon lysis. The amount of labels in the media is measured to determine the level of cytotoxicity the effectors have induced. These traditional methods may generate inconsistent results due to low sensitivity caused by poor loading efficiency and high spontaneous release of the reagents. In this work, we demonstrate a novel cytotoxicity assay using the Celigo imaging cytometry method. Utilizing imaging cytometry, direct cell counting of live fluorescent target cells can be performed, which is a direct method for assessment of cytotoxicity. Human NK cells from one healthy donor were used as effectors, and K562 (suspension) and IMR32 (adherent) were used as the target cells. Both target cells were first stained with Calcein AM, and seeded at 10,000 cells/well in a standard 96-well microplate. The donor NK cells were then added to each well at Effector-to-Target (E:T) ratios 10:1, 5:1, 2.5:1, 1.25:1, 0.625:1, and 0.3125:1. The 96 well plate was then scanned and analyzed using Celigo imaging cytometer at t = 1, 2, 3, and 4 h to measure the% lysis of target cells. The results showed increasing% lysis as incubation time and E:T ratio increased. The propose Celigo imaging cytometry is an accurate and simple method for direct quantification of cytotoxicity. Citation Format: Leo Li-Ying Chan, Kelsey Rosbach, Srinivas S. Somanchi, Dean Lee. Quantification of natural killer cell-mediated cytotoxicity using Celigo imaging cytometry. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1303. doi:10.1158/1538-7445.AM2015-1303
Deep Lamellar Endothelial Keratoplasty Clinical Outcome: The 13- to 18-year Follow-up
Authors: Hilde C.M. Hooijmaijers, Marina Rodriguez-Calvo-de-Mora, Korine van Dijk, Lisanne Ham, Carla Nieuwendaal, Gerrit R.J. Melles
Journal: Ophthalmology (2016)
Retrospective study of safety and efficacy of oxycodone for oxycodone-naive patients with or without hepatic dysfunction
Authors: Takashi Igarashi, Kentarou Abe, Tomofumi Miura, Shinya Motonaga, Naoko Yoshino, Yasuhiko Ichida, Hideaki Hasuo, Yoshihisa Matsumoto, Hiroya Kinoshita, Shinichiro Saito
Journal: Annals of Oncology (2015)
Low-Dose Total Body Irradiation (TBI) Followed by Donor Lymphocyte Infusion Increases Donor T-Cell Chimerism Levels in Patients with Low Donor T-Cell Chimerism after Nonmyeloablative Conditioning.
Authors: Frederic Baron, E. Willems, E. Baudoux, N. Wanten, M.T. Closon, N. Witvrouw, K. Hafraoui, P. Frere, Georges Fillet, Yves Beguin
Journal: Blood (2006)